Adaptive Biotechnologies ADPT Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's contract liabilities?
- Adaptive Biotechnologies (ADPT) reported contract liabilities of $807K in Q1 2026.
- How has Adaptive Biotechnologies's contract liabilities changed year-over-year?
- Adaptive Biotechnologies's contract liabilities decreased by 96.7% year-over-year, from $24.81M to $807K.
- What is the long-term trend for Adaptive Biotechnologies's contract liabilities?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's contract liabilities has grown at a -63.9% compound annual growth rate (CAGR), from $163.62M to $1.01M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.